Background : Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity and mortality in the developing countries. There is need to provide the most effective management to pre-eclamptic and eclamptic patients. There is now evidence that magnesium sulphate is the most effective anticonvulsant. Method : In this article, a literature review was made on the contribution of pre-eclampsia and eclampsia to maternal mortality and how it can be curtailed by the use of magnesium sulphate. Results : The drug is administered by the Pritchard or Zuspan regimen, although modifications in the two protocols have been reported. Conclusion : A Nigerian national protocol has been developed on its use. There is need for further tra...
Currently the preferred anticonvulsant used to treat and prevent fits in eclampsia is magnesium sulp...
Background: Preferred anticonvulsant used to treat and prevent fits in eclampsia currently is magnes...
Background: Continuing the administration of magnesium sulphate for 24 hours after the last fit in p...
Background : Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity an...
Background : Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity an...
Background : Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity an...
Eclampsia contributes significantly to maternal and perinatal morbidity and mortality in Nigeria. Th...
Background: Maternal and perinatal mortality and morbidity remains high during pregnancy in the pres...
A case control study, undertaken in the department of Obstetrics and Gynecology in a tertiary referr...
Background: Magnesium sulphate use in the prevention of seizures resulting from preeclampsia and ecl...
Abstract Background Continuing the administration of magnesium sulphate for 24 hours after the last ...
The aim of this study was to evaluate whether a new low-cost strategy for the introduction of magnes...
Background: Eclampsia is defined as the occurrence of one or more convulsions in association with th...
OBJECTIVE: To review systematically the magnesium sulphate (MgSO4) dosing regimens tested in low and...
Eclampsia has been graded as fatal and dreadful disease even before Christ and is the important caus...
Currently the preferred anticonvulsant used to treat and prevent fits in eclampsia is magnesium sulp...
Background: Preferred anticonvulsant used to treat and prevent fits in eclampsia currently is magnes...
Background: Continuing the administration of magnesium sulphate for 24 hours after the last fit in p...
Background : Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity an...
Background : Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity an...
Background : Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity an...
Eclampsia contributes significantly to maternal and perinatal morbidity and mortality in Nigeria. Th...
Background: Maternal and perinatal mortality and morbidity remains high during pregnancy in the pres...
A case control study, undertaken in the department of Obstetrics and Gynecology in a tertiary referr...
Background: Magnesium sulphate use in the prevention of seizures resulting from preeclampsia and ecl...
Abstract Background Continuing the administration of magnesium sulphate for 24 hours after the last ...
The aim of this study was to evaluate whether a new low-cost strategy for the introduction of magnes...
Background: Eclampsia is defined as the occurrence of one or more convulsions in association with th...
OBJECTIVE: To review systematically the magnesium sulphate (MgSO4) dosing regimens tested in low and...
Eclampsia has been graded as fatal and dreadful disease even before Christ and is the important caus...
Currently the preferred anticonvulsant used to treat and prevent fits in eclampsia is magnesium sulp...
Background: Preferred anticonvulsant used to treat and prevent fits in eclampsia currently is magnes...
Background: Continuing the administration of magnesium sulphate for 24 hours after the last fit in p...